drugset / Trial / NCT02937168
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is an exploratory study with the following primary objectives: 1) to establish that PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from participants with severe asthma and an eosinophilic phenotype and 2) to examine the utility of PET/CT for demonstrating that reslizumab produces a reduction in lung inflammation in participants with severe asthma and an eosinophilic phenotype .
Timeline
- Start
- 2017-05-08
- Primary completion
- 2017-05-24
- Completion
- 2017-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Reslizumab | Monoclonal antibody | 3 mg/kg | Intravenous |